MedPath

Meloxicam

Generic Name
Meloxicam
Brand Names
Anjeso, Mobic, Qmiiz, Vivlodex
Drug Type
Small Molecule
Chemical Formula
C14H13N3O4S2
CAS Number
71125-38-7
Unique Ingredient Identifier
VG2QF83CGL
Background

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.

Indication

Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain.

Meloxicam, in combination with bupivacaine, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Associated Conditions
Dental Pain, Neuropathic Pain, Osteoarthritis (OA), Pain, Inflammatory, Pauciarticular juvenile rheumatoid arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Postoperative pain, Rheumatoid Arthritis
Associated Therapies
-
kidney.org
·

Chronic kidney disease (CKD) - Symptoms, causes

CKD is diagnosed via eGFR and uACR tests. Management focuses on slowing progression, reducing cardiovascular risk, and treating complications. Medications, diet adjustments, and lifestyle changes are key. Avoid NSAIDs to protect kidney health.
biobuzz.io
·

Philadelphia-area life sciences industry nears 900 layoffs since 2022

Philadelphia-area life sciences industry nears 900 layoffs since 2022 due to reduced investment and focus on late-stage development, with companies like Verrica Pharmaceuticals and Spark Therapeutics cutting jobs.
© Copyright 2025. All Rights Reserved by MedPath